ArticleBJR open2025
HyperArc radiotherapy for unresectable benign orbital tumours-cohort study and dosimetric comparison study.
Article in BJR open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To report the clinical application, dosimetric features, efficacy, and toxicity profile of HyperArc (HA) for benign orbital tumours not amenable to surgical resection. Methods: A retrospective interventional cohort study. Gross target volume included the radiologically evident tumour and the optic nerve (excluded in case of haemangioma). Dosimetry was compared between HA and volumetric modulated arc therapy (VMAT) radiotherapy. Patients were treated with HA and followed-up clinically and radiologically for response and toxicity assessment. Results: Eight patients were included in our study, six patients with an optic nerve sheath meningioma, one cavernous haemangioma and one orbital schwannoma. All patients demonstrated tumour regression, mean tumour volume prior to treatment of was 4916 mm Conclusion: This is the first reported clinical application of HA for benign orbital tumours. HA was an effective and well tolerated treatment modality. HA offered better dosimetry for some of the OARs compared to VMAT. Advances in knowledge: This is the first article reporting the use of the HA system for planning and delivery of radiotherapy for orbital tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.